Publication of new data demonstrates significantly superior efficacy of XF-73 compared to a leading topical antibiotic against MRSA in skin infection models The publication, entitled, “Efficacy of a ...

Destiny Pharma plc (GB:DEST) has released an update. Destiny Pharma plc, a clinical-stage biotechnology company, will hold its 2024 Annual General Meeting (AGM) to discuss the progress and future ...

Phase 3 can use similar primary endpoint to the very successful Phase 2b clinical study New European report underpins clinical need and market opportunity of XF-73 Nasal Brighton, United Kingdom ...

The title of the presentation is, ‘Inhibition of MRSA Infection by Exeporfinium Chloride (XF-73) in an In Vivo Burn Wound Model.’ The data was generated from a study in which XF-73 was applied ...

XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government's NIAID Brighton, United Kingdom, 15th November 2022 - Destiny Pharma ...

Please provide your email address to receive an email when new articles are posted on . An exeporfinium chloride nasal gel called XF-73 was safe for patients and effectively decreased the burden ...

Destiny Pharma is providing the Company's proprietary XF-73 drug to the CF Foundation National Resource Center for Microbiology at the Seattle Children's Hospital. The studies will involve ...

y Pharma PLC on Thursday said that its priority remains promoting its XF-73 Nasal antibacterial drug. The Brighton, England-based biotechnology... Subscribe now to see this Premium News article ...

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return ...

Destiny Pharma has listed on London’s AIM exchange. The IPO gives Destiny £15.3 million ($19.8 million) to assess lead candidate XF-73 in the prevention of postsurgical staphylococcal ...

The Brighton, U.K.-based company’s pitch was to use the money to fund the phase 2b trial of XF-73, a nasal drug designed to prevent post-surgery staphylococcal infections. That trial read out in ...

Destiny Pharma bosses said they believed that delisting would give it a “realistic chance” of securing the funding needed to progress XF-73 Nasal. Biotech business Destiny Pharma has become ...